Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
暂无分享,去创建一个
[1] J. Zwerina,et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. , 2008, Arthritis and rheumatism.
[2] J. Muddle,et al. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. , 2006, The American journal of pathology.
[3] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[4] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[5] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[6] C. Daniels,et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. , 2004, The Journal of clinical investigation.
[7] H. Kantarjian,et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia , 2004, Cancer.
[8] R. Gay,et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[9] Oliver Distler,et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.